Human saphenous vein (hSV) and synthetic grafts are commonly used conduits in vascular grafting, despite high failure rates. Decellularising hSVs (D-hSVs) to produce vascular scaffolds might be an effective alternative. We assessed the effectiveness of a detergent-based method using 0% to 1% sodium dodecyl sulphate (SDS) to decellularise hSV. Decellularisation effectiveness was measured in vitro by nuclear counting, DNA content, residual cell viability, extracellular matrix integrity and mechanical strength. Cytotoxicity was assessed on human and porcine cells. The most effective SDS concentration was used to prepare D-hSV grafts that underwent preliminary in vivo testing using a porcine carotid artery replacement model. Effective decellularisation was achieved with 0.01% SDS, and D-hSVs were biocompatible after seeding. In vivo xeno-transplantation confirmed excellent mechanical strength and biocompatibility with recruitment of host cells without mechanical failure, and a 50% patency rate at 4-weeks. We have developed a simple biocompatible methodology to effectively decellularise hSVs. This could enhance vascular tissue engineering toward future clinical applications.
Bibliographical noteFunding Information:
We thank the staff at the University of Bristol Translational Biomedical Research Centre, a national research facility for large animal co-funded by the British Heart Foundation and the Medical Research Council. In addition, we thank the staff at the Amrita Institute of Medical Sciences and Research Centre for undertaking the mechanichal strenght tests.
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grants awarded to Ascione: the Majlis Amanah Rakyat (MARA; Malay: People's Trust Council) (a Malaysian Government Agency PhD studentship in support of N Sulaiman with RA, MSS and SJG as supervisors), the British Heart Foundation (BHF) (BHF IG/14/2/30991, and BHF/PG/16/104/32652), and the Medical Research Council (MRC) (MRC MR/L012723/1).
© The Author(s) 2021.
- Tissue Engineering
- Vascular Graft